London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.
An injectable collagen scaffold that recruits the joint's own cells to repair cartilage damage, ChondroFiller offers structural regeneration earlier in the treatment pathway than knee replacement. Evidence from appropriately selected candidates shows 70–85% achieve meaningful symptom relief within three to five years.
ChondroFiller injection—a cell-free collagen scaffold delivered via ultrasound in an outpatient appointment—offers an alternative to surgery for focal ankle cartilage lesions, recruiting the patient's own progenitor cells to repair the defect.
The collagen scaffold draws progenitor cells inward, reaching a 2.4-fold DNA increase by day 14; the four-to-six-week Protect phase must restrict loading because the scaffold's mechanical maturation is independent of pain scores.
Patients with knee osteoarthritis referred to physiotherapy within one year of symptoms experience significantly greater pain relief than those referred later — an 8.33-point improvement on a 100-point scale — indicating early intervention is the highest-yield point in the treatment pathway.
Lying down removes the protective effects of movement and muscle engagement, concentrating pressure on already-affected joint surfaces for hours at a time. Where pain occurs — outer hip, deep groin, or radiating leg — identifies the underlying cause without imaging.
Advanced knee osteoarthritis typically has two concurrent pain sources—cartilage wear and synovial inflammation—that conventional single-agent injections address incompletely. The CFI+ protocol treats both by placing ChondroFiller, a collagen scaffold, on the damaged cartilage and injecting Arthrosamid, a polyacrylamide hydrogel, into the joint lining in one outpatient appointment.
